Cite
HARVARD Citation
Taskinen, M. et al. (2021). Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes. Arteriosclerosis, thrombosis, and vascular biology. 41 (2), p. . [Online].